Compare TITN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TITN | RLMD |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.3M | 461.9M |
| IPO Year | 2007 | 2012 |
| Metric | TITN | RLMD |
|---|---|---|
| Price | $23.37 | $4.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $19.00 | $12.40 |
| AVG Volume (30 Days) | 302.0K | ★ 936.8K |
| Earning Date | 05-21-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,427,107,000.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $13.21 | $1.45 |
| 52 Week High | $26.90 | $8.00 |
| Indicator | TITN | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 61.10 | 28.25 |
| Support Level | $15.86 | $3.98 |
| Resistance Level | $25.00 | $4.44 |
| Average True Range (ATR) | 1.70 | 0.19 |
| MACD | 0.57 | -0.00 |
| Stochastic Oscillator | 68.44 | 9.21 |
Titan Machinery Inc owns and operates a network of full-service agricultural and construction equipment stores. The company sells and repairs agricultural equipment, including machinery and attachments for large-scale farming and home and gardening purposes, as well as construction equipment. It operates through following segments: The Agriculture segment sells, services, and rents machinery and related parts and attachments, for uses ranging from large-scale farming to home and garden use, The construction segment sells, services, and rents machinery, and related parts and attachments, for uses ranging from heavy construction to light industrial machinery use, and the Europe and Australia segments.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.